I hear what you are saying but go back and listen to Biotech...

I hear what you are saying but go back and listen to Biotech Editor Mark’s comments, especially about timelines and how pivot points come well before the end of timelines.

Look at drugs like Keytruda, they are still doing research for years after it was sold. Given how many different drugs & cancers Bisantrene is effective with whoever owns the drug could keep generating new IP, new molecules, new formulas for years to come. Doesn’t mean we will be floundering at this SP until 2029.

Looking at DXB as best example, signing off on regional deals while in phase 3, well before the end of timelines but has seen SP go from lows of 5c to 41.5c or so, future revenue and funds secured no need to raise and haven’t had to dilute. If management of RAC are savvy enough and decent negotiators then no reason we couldn’t see similar “pivot points” that change the value of the company, the SP & eventually more M&A activity.